AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people ...

AbbVie Inc. (ABBV) on Thursday reported second-quarter earnings of $938 million. The North Chicago, Illinois-based company said it had net ...

AbbVie Inc. (NYSE: ABBV) is reportedly negotiating the acquisition of Gilgamesh Pharmaceuticals, a privately held mental ...

AbbVie has reported topline outcomes from the first of two trials of the Phase III UP-AA programme, assessing Rinvoq (upadacitinib).

AbbVie (ABBV) came out with quarterly earnings of $2.97 per share, beating the Zacks Consensus Estimate of $2.89 per share. This compares to earnings of $2.65 per share a year ago. These figures are ...

AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil ...

A look at the shareholders of AbbVie Inc. (NYSE:ABBV) can tell us which group is most powerful. We can see that institutions ...

According to JPMorgan, AbbVie Inc. (NYSE:ABBV) is in a solid spot as it won’t lose any significant exclusivity events until the mid-2030s, Moveover, the firm states that Skyrizi and Rinvoq can grow ...

Shares of AbbVie Inc. ABBV advanced 1.22% to $187.11 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

This was the stock's third consecutive day of losses.

Glenmark Pharmaceuticals is set to become net cash positive through its licensing agreement with AbbVie Inc. This move aims to improve the company's financial stability and reduce its debt. The deal ...